GlaxoSmithKline (NYSE: GSK ) reported earnings on Feb. 7. Here are the numbers you need to know. The 10-second takeaway For the quarter ended Dec. 31 (Q4), GlaxoSmithKline missed estimates on revenues and whiffed on earnings per share. Compared to the pr

Stevenage Bioscience Catalyst (SBC), the UK's first open innovation bioscience campus, is pleased to announce that it is now open for business. In addition, it has welcomed its first tenant, Aptiv Solutions, which has taken space in the Incubator buildin

Thursday, February 9, 6:56 AM Vodafone (VOD) follows other firms, moving cash out of Greece "every evening," to guard against an exit from the euro, according to its CFO Andy Halford. GlaxoSmithKline (GSK) takes it a step further, moving its cash from al

Big pharma companies have upped outsourcing in recent years to cut fixed costs ahead of the patent cliff. GlaxoSmithKline (GSK), however, is moving some manufacturing and other work back in-house. “We're bringing in-house a lot of the things that for the

View the rest of this gallery online at http://citywire.co.uk/money/gallery/a564667 © 2012 Citywire.co.uk. All Rights Reserved. Citywire Financial Publishers Ltd. is authorised and regulated by the Financial Services Authority no: 222178 to provide inves

There are relatively few drug companies that offer a truly balanced opportunity for investors. In many cases investors have to factor in the risk of significant near-term patent losses or uninspiring (or highly risky) pipelines. GlaxoSmithKline (GSK) is

LONDON: GlaxoSmithKline is getting more bang for its buck in drug research, underpinning expectations for a return to sales and margin growth despite fourth-quarter results that fell short of analyst forecasts. Britain’s biggest drugmaker said on Tuesday

The former Avandia users who filed the lawsuits reached an accord with GlaxoSmithKline in a mediation ordered by U.S. District Judge Cynthia Rufe in Philadelphia, according to an article that recently ran on Bloomberg.com. Judge Rufe had set a 75-day dea

Registering allows you to sign up for any of our free emails, participate in polls or comment on stories. If you are trying to get to subscriber-only content, or wish to receive weekly copies of Ad Age, then you'll need to subscribe. We offer several dif

GlaxoSmithKline ( GSK ) reported fourth quarter earnings of 90 cents per ADS, below the Zacks Consensus Estimate of 95 cents but above the year-ago loss of 24 cents per ADS. Revenues fell 2% year over year at constant exchange rates ("CER") to $11.2 bill